Gibt es Fortschritte in der Tumorschmerztherapie? Studienlage zu OROS®-Hydromorphon

Zusammenfassung

Der vorliegende Artikel gibt eine Übersicht über die zahlreichen Studien zu verschiedenen Indikationen mit OROS®-Hydromorphon, an denen insgesamt mehr als 1500 Patienten teilgenommen haben. OROS®-Hydromorphon besitzt eine flache und gleichmäßige Pharmakokinetik und bewirkt eine über 24 h kontinuierlich anhaltende Analgesie. Es zeichnet sich durch eine gute, dem Morphin tendenziell überlegene Verträglichkeit aus und geht mit positiven Effekten auf Schlaf und Lebensqualität der Patienten einher.

Abstract

This article gives an overview of the numerous studies for various indications with OROS-Hydromorphon. More than 1500 patients have taken part in these studies. OROS-Hydromorphon has a plan and constant pharmacokinetic and results in an ongoing analgesia for 24 hours. It is characterizes by a good tolerability trending to be superior to Morphin. It also has a positive effect on sleeping ability and quality of life.

OROS® - Hydromorphon - Jurnista - Compliance - Tumorschmerz - Schlaf - Lebensqualität

OROS - Hydromorphone - Jurnista - Compliance - tumor related pain - sleep - quality of life

Literatur

• 1 Hanna M, Thipphawong J. A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain.  BMC Palliative Care. 2008;  7 17
• 2 Hale M, Tudor I C, Khanna S. et al . Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.  Clin Ther. 2007;  29 (5) 874-888
• 3 Kurita G P, Pimenta C A. Compliance with chronic pain treatment: study of demographic, therapeutic and psychosocial variables.  Arq Neuropsiquiatr. 2003;  61 (2B) 416-425
• 4 Sale J E, Gignac M, Hawker G. How „bad” does the pain have to be? A qualitative study examining adherence to pain medication in older adults with osteoarthritis.  Arthritis Rheum. 2006;  55 (2) 272-278
• 5 Claxton A J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance.  Clin Ther. 2001;  23 (8) 1296-1310
• 6 Sabaté E. (editor). Adherence to long-term therapies: evidence for action.  Geneva, Switzerland: World Health Organization. 2003; 
• 7 Ferrell B, Wiscom C, Wenzel C. et al . Effects of controlled-released morphine on quality of life for cancer pain.  Oncology Nursing Forum. 1989;  16 (4) 521-526
• 8 Gupta S, Satyhan G. Pharmacokinetic profile of a 24-hour controlled-release OROS® formulation of hydromorphone in the presence and absence of food.  J Pain Symptom Manage. 2007;  33 S19-S24
• 9 Sathyan G, Xu E, Thipphawong J. et al . Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone.  BMC Clin Pharmacol. 2007;  7 3
• 10 Palangio M, Northfelt D W, Portenoy R K. et al . Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.  J Pain Symptom Manage. 2002;  23 (5) 355-368
• 11 Sarhill N, Walsh D, Nelson K A. Hydromorphone: pharmacology and clinical applications in cancer patients.  Support Care Cancer. 2001;  9 (2) 84-96
• 12 Wallace M,  Rauck R L,  Moulin D. et al . Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain.  J Int Med Res. 2008;  36 (2) 343-352
• 13 Wallace M, Skowronski R, Khanna S. et al . Efficacy and safety evaluation of once-daily OROS® hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).  Curr Med Res Opin. 2007;  23 (5) 981-989
• 14 Wallace M, Moulin D E, Rauck R L. et al . Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.  J Opioid Manag. 2009;  5 (2) 97-105